Relay Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 5, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 5, 2025
RLAY$19.94-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(77,065) | $(81,387) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 1,208 | 1,395 |
| Stock compensation expense | 19,325 | 27,188 |
| Net amortization of premiums and discounts on investments | (1,597) | (3,665) |
| Change in fair value of contingent consideration liability | — | (1,832) |
| Changes in assets and liabilities: | ||
| Prepaid expenses and other current assets | (3,931) | (475) |
| Operating lease assets and liabilities, net | 283 | 350 |
| Accounts payable and accrued expenses | (3,446) | 7,645 |
| Deferred revenue | (7,679) | — |
| Other liabilities | (308) | 458 |
| Net cash used in operating activities | (73,210) | (50,323) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (384) | (1,780) |
| Purchases of investments | (21,971) | (190,784) |
| Proceeds from maturities and sales of investments | 64,820 | 203,095 |
| Net cash provided by investing activities | 42,465 | 10,531 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock through Private Placement, net | — | 29,803 |
| Proceeds from issuance of common stock via at-the-market offerings, net | — | 17,932 |
| Proceeds from issuance of common stock upon exercise of stock options | — | 1,187 |
| Net cash provided by financing activities | — | 48,922 |
| Net (decrease) increase in cash, cash equivalents, and restricted cash | (30,745) | 9,130 |
| Cash, cash equivalents, and restricted cash at beginning of period | 126,406 | 146,443 |
| Cash, cash equivalents, and restricted cash at end of period | $95,661 | $155,573 |
| Supplemental disclosure of non-cash activities: | ||
| Periodic change in additions of property and equipment within current liabilities | $61 | $(1,411) |
| Periodic change in costs to obtain license agreement within current liabilities | $(2,508) | $— |
Reconciliation of Cash, Cash Equivalents, and Restricted Cash from Balance Sheets to Statement of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| 2025 | 2024 | |
| (in thousands) | ||
| Cash and cash equivalents | $93,542 | $152,866 |
| Restricted cash | 2,119 | 2,707 |
| Cash, cash equivalents, and restricted cash per statements of cash flows | $95,661 | $155,573 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.